442 related articles for article (PubMed ID: 19326431)
1. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
Narayanan NK; Nargi D; Randolph C; Narayanan BA
Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
3. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
4. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.
Zhang W; Zhu J; Efferson CL; Ware C; Tammam J; Angagaw M; Laskey J; Bettano KA; Kasibhatla S; Reilly JF; Sur C; Majumder PK
Cancer Res; 2009 Sep; 69(18):7466-72. PubMed ID: 19738074
[TBL] [Abstract][Full Text] [Related]
6. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
[TBL] [Abstract][Full Text] [Related]
7. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
8. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
[TBL] [Abstract][Full Text] [Related]
9. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines.
Benitez DA; Pozo-Guisado E; Alvarez-Barrientos A; Fernandez-Salguero PM; Castellón EA
J Androl; 2007; 28(2):282-93. PubMed ID: 17050787
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer.
Shankar S; Srivastava RK
Int J Oncol; 2007 Apr; 30(4):905-18. PubMed ID: 17332930
[TBL] [Abstract][Full Text] [Related]
12. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
13. Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothiocyanate.
Barve A; Khor TO; Hao X; Keum YS; Yang CS; Reddy B; Kong AN
Pharm Res; 2008 Sep; 25(9):2181-9. PubMed ID: 18437538
[TBL] [Abstract][Full Text] [Related]
14. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms.
Hudson TS; Hartle DK; Hursting SD; Nunez NP; Wang TT; Young HA; Arany P; Green JE
Cancer Res; 2007 Sep; 67(17):8396-405. PubMed ID: 17804756
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
[TBL] [Abstract][Full Text] [Related]
17. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
18. Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor.
Guo H; Xu YM; Ye ZQ; Yu JH; Hu XY
Pharmazie; 2013 Jun; 68(6):431-4. PubMed ID: 23875250
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol induces cell cycle arrest in human gastric cancer MGC803 cells via the PTEN-regulated PI3K/Akt signaling pathway.
Jing X; Cheng W; Wang S; Li P; He L
Oncol Rep; 2016 Jan; 35(1):472-8. PubMed ID: 26530632
[TBL] [Abstract][Full Text] [Related]
20. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
